Retifanlimab (Genetical Recombination)



Retifanlimab is a recombinant anti-PD-1 monoclonal antibody whose complementarity-determining regions are derived from mouse antibody and other regions are derived from human IgG4. In the H-chain, the amino acid residue is substituted at 1 position (S227P), and K446 at the C-terminus is deleted. Retifanlimab is produced in CHO cells. Retifanlimab is a glycoprotein (molecular weight: ca. 148,000) composed of 2 H-chains (γ4-chains) consisting of 445 amino acid residues each and 2 L-chains (κ-chains) consisting of 218 amino acid residues each.

[2079108-44-2]